Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma

Genetics and Molecular Research

Volumn 15, Issue 1, 2016, Pages

  Han, T D ^a   Shang, D H ^a   Tian, Y ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Docetaxel; G2 M cell cycle; Human renal cell carcinoma

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTINEOPLASTIC AGENT; MAPK1 PROTEIN, HUMAN; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961684963     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/gmr.15017321     Document Type: Article

References (32)

1. Atmaca A, Al-Batran SE, Werner D, Pauligk C, et al. (2013). A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br. J. Cancer 108: 265-270. http: //dx. doi. org/10. 1038/bjc. 2012. 555
2. Breit SN, Johnen H, Cook AD, Tsai VW, et al. (2011). The TGF-b superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29: 187-195. http: //dx. doi. org/10. 3109/08977194. 20 11. 607137
3. Brown DA, Ward RL, Buckhaults P, Liu T, et al. (2003). MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin. Cancer Res. 9: 2642-2650.
4. Brown DA, Lindmark F, Stattin P, Bälter K, et al. (2009). Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin. Cancer Res. 15: 6658-6664. http: //dx. doi. org/10. 1158/1078-0432. CCR-08-3126
5. Brown DA, Hance KW, Rogers CJ, Sansbury LB, et al. (2012). Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidemiol. Biomarkers Prev. 21: 337-346. http: //dx. doi. org/10. 1158/1055-9965. EPI-11-0786
6. Caraglia M, Giuberti G, Marra M, Di Gennaro E, et al. (2005). Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front. Biosci. 10: 2566-2575. http: //dx. doi. org/10. 2741/1720
7. Cariello NF, Romach EH, Colton HM, Ni H, et al. (2005). Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. Toxicol. Sci. 88: 250-264. http: //dx. doi. org/10. 1093/toxsci/kfi273
8. Corre J, Labat E, Espagnolle N, Hébraud B, et al. (2012). Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 72: 1395-1406. http: //dx. doi. org/10. 1158/0008-5472. CAN-11-0188
9. Darido C, Georgy SR, Wilanowski T, Dworkin S, et al. (2011). Targeting of the tumor suppressor GRHL3 by a miR-21- dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 20: 635-648. http: //dx. doi. org/10. 1016/j. ccr. 2011. 10. 014
10. Engels FK, Sparreboom A, Mathot RA and Verweij J (2005). Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93: 173-177. http: //dx. doi. org/10. 1038/sj. bjc. 6602698
11. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, et al. (2005). Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J. Urol. 173: 1893-1896. http: //dx. doi. org/10. 1097/01. ju. 0000158157. 57981. 80
12. Mac Gabhann F, Annex BH and Popel AS (2010). Gene therapy from the perspective of systems biology. Curr. Opin. Mol. Ther. 12: 570-577.
13. Henry NL and Hayes DF (2012). Cancer biomarkers. Mol. Oncol. 6: 140-146. http: //dx. doi. org/10. 1016/j. molonc. 2012. 01. 010
14. Jane SM, Ting SB and Cunningham JM (2005). Epidermal impermeable barriers in mouse and fly. Curr. Opin. Genet. Dev. 15: 447-453. http: //dx. doi. org/10. 1016/j. gde. 2005. 05. 005
15. Jiang CC, Yang F, Thorne RF, Zhu BK, et al. (2009). Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 11: 436-447. http: //dx. doi. org/10. 1593/neo. 09208
16. Kumar B, Sinclair J, Khandrika L, Koul S, et al. (2009). Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. Int. J. Oncol. 34: 1557-1564.
17. Li Y, Mori T, Hata H, Homma Y, et al. (2004). NIRF induces G1 arrest and associates with Cdk2. Biochem. Biophys. Res. Commun. 319: 464-468. http: //dx. doi. org/10. 1016/j. bbrc. 2004. 04. 190
18. Maggioni D, Nicolini G, Chiorazzi A, Meregalli C, et al. (2010). Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. J. Neurosci. Res. 88: 3171-3179. http: //dx. doi. org/10. 1002/jnr. 22465
19. Mori T, Li Y, Hata H, Ono K, et al. (2002). NIRF, a novel RING finger protein, is involved in cell-cycle regulation. Biochem. Biophys. Res. Commun. 296: 530-536. http: //dx. doi. org/10. 1016/S0006-291X(02)00890-2
20. Mori T, Ikeda DD, Fukushima T, Takenoshita S, et al. (2011). NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle 10: 3284-3299. http: //dx. doi. org/10. 4161/cc. 10. 19. 17176
21. Parrondo R, de Las Pozas A, Reiner T and Perez-Stable C (2013). ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ 1: e144. http: //dx. doi. org/10. 7717/peerj. 144
22. Porta C and Szczylik C (2009). Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat. Rev. 35: 297- 307. http: //dx. doi. org/10. 1016/j. ctrv. 2008. 12. 003
23. Rein DT, Breidenbach M and Curiel DT (2006). Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2: 137-143. http: //dx. doi. org/10. 2217/14796694. 2. 1. 137
24. Staff AC, Bock AJ, Becker C, Kempf T, et al. (2010). Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol. Oncol. 118: 237-243. http: //dx. doi. org/10. 1016/j. ygyno. 2010. 05. 032
25. Vainas O, Ariad S, Amir O, Mermershtain W, et al. (2012). Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. Br. J. Cancer 107: 814-822. http: //dx. doi. org/10. 1038/bjc. 2012. 316
26. van Soest RJ, de Morrée ES, Shen L, Tannock IF, et al. (2014). Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur. Urol. 66: 330-336. http: //dx. doi. org/10. 1016/j. eururo. 2013. 08. 007
27. Verma M (2012). Epigenetic biomarkers in cancer epidemiology. Methods Mol. Biol. 863: 467-480. http: //dx. doi. org/10. 1007/978- 1-61779-612-8_28
28. Wagner EF and Nebreda AR (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9: 537-549. http: //dx. doi. org/10. 1038/nrc2694
29. Wallin U, Glimelius B, Jirström K, Darmanis S, et al. (2011). Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br. J. Cancer 104: 1619-1627. http: //dx. doi. org/10. 1038/bjc. 2011. 112
30. Wilson C, Scullin P, Worthington J, Seaton A, et al. (2008). Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br. J. Cancer 99: 2054-2064. http: //dx. doi. org/10. 1038/sj. bjc. 6604804
31. Xu X, Li Z and Gao W (2011). Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16: 466-475. http: //dx. doi. org/10. 3109/1354750X. 2011. 580006
32. Yang H, Filipovic Z, Brown D, Breit SN, et al. (2003). Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2: 1023-1029.